Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 5/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcodeine SCHEMBL18462800 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL29776979 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL120271 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL12638889 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL16922132 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL24541888 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL120270 | 0.99 | MRGPRX2 (1.00) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL6220787 | 0.98 | MRGPRX2 (0.98) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Norcodeine SCHEMBL7593070 | 0.97 | MRGPRX2 (0.96) | MRGPRX2MAPTOPRM1OPRK1OPRD1 | |
| Codeine SCHEMBL20703798 | 0.89 | OPRM1 (0.83) | MRGPRX2MAPTOPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405301-B2 | Chemical methods | GLAXOWELLCOME AUSTRALIA LTD. (AU) | 2008-07-29 | — | — | US | disclosed |
| US-20040077863-A1 | Chemical methods | GLAXO WELLCOME AUSTRALIA LTD. (AU) | 2004-04-22 | — | — | US | disclosed |
| WO-2002016367-A1 | CHEMICAL METHODS | GLAXO WELLCOME AUSTRALIA LTD (AU) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077863-A1 | Chemical methods | TET2, TET1, DNMT1 | MRGPRX2 2524/4885MAPT 1694/4885OPRM1 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.